Table 14. Sterling in vivo antitumor data for analog 110 (WIN-58161).
Tumor | Drug route/schedule | Max. tolerated total dosea (mg/kg) | %T/Cb | %ILSc |
---|---|---|---|---|
Panc03 | s.c., qd 3-9 | 781 | 17 | |
Colo38 | s.c., qd 3-9 | 504 | 0 | |
Mam16C | s.c., qd 1-4 | 263 | 15 | |
B16 | i.p., qd 1,5,9 | 1500 | 66 | |
P388 | i.p., qd 1,5,9 | 1014 | 90 |
aMaximum non-lethal dose; btumor growth inhibition where T and C are median tumor weights of the treatment and control groups respectively; cpercent increased life span.